<abstract xmlns="http://www.w3.org/1999/xhtml"><p>The treatment paradigm in renal cell carcinoma (RCC) is rapidly changing. The incidental finding of small renal tumours combined with the development of novel therapeutic agents targeting the vascular endothelial growth factor (VEGF) or the mammalian target of rapamycin (mTOR) pathways or inhibiting the interaction of the programmed death 1 (PD 1) receptor with its ligand have dramatically improved the prognosis of patients suffering from this malignancy. At the same time, the availability of multiple effective options with similar indications complicates the development and applicability of guidelines in this disease. We conducted a systematic review of the existing guidelines. Our study revealed areas of agreement as well as of discrepancies amongst the published scientific papers included. By critically evaluating these areas, we developed a therapeutic algorithm for RCC. We suggest that this methodology can define the practices of wide applicability and areas of future research.</p></abstract>

The treatment paradigm in renal cell carcinoma (RCC) is rapidly changing. The incidental finding of small renal tumours combined with the development of novel therapeutic agents targeting the vascular endothelial growth factor (VEGF) or the mammalian target of rapamycin (mTOR) pathways or inhibiting the interaction of the programmed death 1 (PD 1) receptor with its ligand have dramatically improved the prognosis of patients suffering from this malignancy. At the same time, the availability of multiple effective options with similar indications complicates the development and applicability of guidelines in this disease. We conducted a systematic review of the existing guidelines. Our study revealed areas of agreement as well as of discrepancies amongst the published scientific papers included. By critically evaluating these areas, we developed a therapeutic algorithm for RCC. We suggest that this methodology can define the practices of wide applicability and areas of future research.

Developing an algorithm for the management of Renal Cell Carcinoma: focus on metastatic disease

Forum of Clinical Oncology

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

The treatment paradigm in renal cell carcinoma (RCC) is rapidly changing. The incidental finding of small renal tumours combined with the development of novel...

Developing an algorithm for the management of Renal Cell Carcinoma: focus on metastatic disease

Publicado en línea: 30 jun 2017

Páginas: 15 - 21

Recibido: 08 ago 2017

Aceptado: 24 ago 2017

DOI: https://doi.org/10.1515/fco-2015-0025

Palabras clave
Renal cell carcinoma, Metastatic Disease, Therapeutic algorithm

© 2017 Anastasios Kyriazoglou, Ioannis Dimitriadis, Aristotelis Bamias

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Developing an algorithm for the management of Renal Cell Carcinoma: focus on metastatic disease

Publicado en línea: 30 jun 2017

Páginas: 15 - 21

Recibido: 08 ago 2017

Aceptado: 24 ago 2017

DOI: https://doi.org/10.1515/fco-2015-0025

Palabras claveRenal cell carcinoma, Metastatic Disease, Therapeutic algorithm

© 2017 Anastasios Kyriazoglou, Ioannis Dimitriadis, Aristotelis Bamias

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Palabras clave
Renal cell carcinoma, Metastatic Disease, Therapeutic algorithm